Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objectives of this study are to investigate issues or questions about MIRAPEX Tablets as
shown below through the Post Marketing Surveillance (PMS) study upon approval.
- Unexpected adverse events (especially, serious adverse events (SAEs))
- To find out the status of incidence of adverse events under actual practice
- Factors on the safety profile
- Factors on the efficacy profile